EraCal Therapeutics, the Biotech Company Developing Solutions to Different Diseases, Joins SFNV
The preclinical biotech startup, EraCal Therapeutics, which develops drugs using cutting-edge science to treat health and obesity issues, has joined the SFNV.
Switzerland, February 2021 – EraCal Therapeutics, a Swiss producer of biotechnology drugs using cutting-edge technology to treat metabolic syndrome, has joined the SFNV. The company is currently focusing on a pipeline of appetite suppressants to tackle obesity and its metabolic complications. Its lead molecule, Era-107, is an oral appetite suppressor with superior efficacy and safety profile, as demonstrated in three vertebrate species. EraCal is now preparing to carry out further toxicology studies ahead of first-in-human trials.
For more information:
E-mail : info@eracal.ch
Latest Members
Swiss student innovators took the stage at Ecotrophelia Switzerland 2026
Ecotrophelia Switzerland 2026 brought...
planetary raises ~$28 million (CHF 22 million) in funding to scale global fermentation infrastructure and licensing platform
Planetary SA (“planetary” or the...
Healthy eating – can we close the gap between evidence and public belief?
Healthy eating – can we closethe gap...